After a post-pandemic correction—marked by a nosedive in dealmaking activity, a spike in bankruptcies and dried-up financing—M&A activity finally seemed to pick back up for biopharma in 2025. The year opened with the largest deal that would come: Johnson & Johnson’s $14.6 billion play for Intra-Cellular Therapeutics, putting the pharma in a commanding position in the neuroscience space. Besides Intra-Cellular, there was plenty of other exciting activity, especially later in the year, which witnessed two big-ticket bidding wars. Here, BioSpace looks back at the biggest acquisition deals of 2025.
Read the full article: Five Biggest Biopharma Takeovers of 2025 //
Source: https://www.biospace.com/business/five-biggest-biopharma-takeovers-of-2025